Navigation Links
Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
Date:10/26/2007

Promising pre-clinical results support advance to clinical study for third combination chemotherapy from Celator based on the company's proprietary

CombiPlex(TM) technology platform.

PRINCETON, N.J., Oct. 26 /PRNewswire/ -- Celator Pharmaceuticals today announced positive results from preclinical studies to evaluate the optimal ratio of irinotecan and cisplatin to deliver synergistic benefit against a range of tumor cell lines in vitro. The study further worked to develop an effective formulation to maintain the optimal ratio of these drugs in vivo. Results were presented this week in a poster presentation at the AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA.

In the study, combinations of irinotecan and cisplatin were applied to a panel of 20 human and murine tumor cell lines enriched with lung tumor carcinomas in vitro to identify the ratios most likely to deliver synergistic benefit. The combination exhibited strong drug ratio dependent synergy. Using Celator's proprietary CombiPlex technology, researchers then engineered a combination of irinotecan and cisplatin in liposomes to maintain a synergistic 7:1 molar ratio following intravenous administration. The product, known as CPX-571, was compared to a combination of irinotecan and cisplatin administered as free drugs, and to monotherapy with each drug agent administered in a liposome formulation in mice implanted with human solid tumor xenografts. In all tumor models tested, CPX-571 showed a high degree of anti-tumor activity and significantly improved efficacy as compared to the combination of free drugs and to the individual liposomal drug agents.

"In this study we were able to identify the optimal ratio of irinotecan and cisplatin to use in combination chemotherapy and then combine the drugs in a formulation able to maintain that ratio in animal models. Along with our progress in developing CPX-1, curre
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
4. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
5. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
6. RT-PCR Primers for the Study of Apoptosis
7. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
10. Medical College receives $377K to study brain disease
11. Kauffman study shows consistent entrepreneurial growth

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...swire-FirstCall/ -- Peregrine Pharmaceuticals, Inc...tient enrollment in a dose confirmation and dosime...d glioblastoma multiforme (GBM), the deadliest for...l antibody linked to a radioisotope being develope...ecifically targets cells at the center of brain tu...
(Date:12/2/2009)...December 2 Pepscan Holding NV,the...on protein mimicking,technology for the generation...s appointed Wim E.M. Mol, Ph.D. as new Chief Execu...le for all of Pepscans corporate functions and,the... company. He brings to,Pepscan more than 20 years ...
(Date:12/2/2009)...ire/ -- S*BIO Pte Ltd today announced data present...t The American Society of Hematology 51st Annual M...ill be presented on the clinical results from the ...its safety, tolerability and pharmacokinetic/pharm...from 100 to 600 mg. These doses were administered ...
(Date:12/2/2009)...FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ...tical company focused on endocrine therapy and onc... Administration (FDA) has granted Fast Track desig...r compound, perifosine (KRX-0401), for the treatme...Biopharmaceuticals, Inc. ("Keryx") ( KERX), is AEt...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3
...ontinues to Fortify Position in Emerging RNAi Indu... Interfering RNA (siRNA) Structural IP, PALO ALTO...eading developer of targeted, systemic RNA interfe... has licensed key intellectual,property (IP) cover... of,small interfering RNA (siRNA) from the Univers...
...elgium, April 9 ThromboGenics NV,(Euronext Brusse...lar,diseases, eye diseases and cancer, announces t...ts Phase II MITI IV study. The primary purpose of,...ry efficacy of,microplasmin when administered intr...d twelve hours after the onset of the stroke., MI...
...April 8, 2008 Dendreon Corporation,(Nasdaq: DNDN...ously,announced registered direct offering of 8.0 ... purchase up to 8.0 million shares of its common,s...ximately $46 million.,Lazard Capital Markets LLC s...The offering is being made pursuant to previously ...
Other Biology Technology:Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 2Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 3Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 4ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 2ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 3Dendreon Announces Closing of Registered Direct Offering 2
(Date:12/1/2009)...versity cancer researchers have developed a tumor... and blocks the growth of new tumor blood vessels.... kill cancer cells oncolytic viruses might be mo...ey also carry a gene for a protein that inhibits b...statin, is normally produced in the brain. In this...
(Date:12/1/2009)... attacks by sharks can be solved with a new techni...mp they put on their victims, according to a Unive...In a method analogous to analyzing human fingerpri...ely comparing shark bites to the jaws and teeth of...ctor of the International Shark Attack File, which...
(Date:12/1/2009)...bominable mystery, and it is a question which has ...id flowering plants evolve and how did they come t...Ecology Letters reveals the evolutionary trigger ...r competitive advantage over rival species, leadin...study, by Dr Tim Brodribb and Dr Taylor Field of ...
Breaking Biology News(10 mins):Tumor-attacking virus strikes with 'one-two punch' 2New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3How did flowering plants evolve to dominate Earth? 2Methane gas likely spewing into the oceans through vents in sea floor 9770 1Methane gas likely spewing into the oceans through vents in sea floor 9770 2Methane gas likely spewing into the oceans through vents in sea floor 9770 3Boron based compounds trick a biomedical protein 9768 1Boron based compounds trick a biomedical protein 9768 2Childrens Hospitals and Clinics of Minnesota Welcomes Twin Cities Businesswoman Molly Culligan to its Board of Directors 56066 1Childrens Hospitals and Clinics of Minnesota Welcomes Twin Cities Businesswoman Molly Culligan to its Board of Directors 56066 2
...ction between the body, mind and spirit has been t...some 20 years. The notion that psychosocial and so...ealth and preventing disease became crystallized a...Cousins. In the 1970s, Cousins, then a writer and ...s diagnosed with an autoimmune disease. He theoriz...
...ction affects millions of people around the world,...and psychological difficulties to physical and hea...uriosity or peer pressure, but in some animals, su...ul early life event, such as social isolation. A n...n the animal,s response to cocaine. , The study,...
...itute for Research in Immunology and Cancer (IRIC)...g a large quantity of laboratory stem cells from a...ne marrow. The multidisciplinary team, directed by... the development of a revolutionary treatment base...dvance stem cell research and could have major imp...
Other Biology News:Laughter remains good medicine 2Laughter remains good medicine 3Early isolation linked to enhanced response to cocaine 2World premiere in stem cell research in Montreal 2
BD Falcon TufRol Cell Culture Flask, 25 cm2 from BD Biosciences - Discovery Labware
...lly clear polystyrene with frosted labeling surfac...s for cell counting. 100% integrity tested. Linkag...d to easily match Cornings product number. If show...d Sigma-Aldrich number (Z71,693-6) or contact cust...
...lly clear polystyrene with frosted labeling surfac...s for cell counting. 100% integrity tested. Linkag...d to easily match Cornings product number. If show...d Sigma-Aldrich number (C0177) or contact customer...
BD Falcon Automated Cell Culture Flask from BD Biosciences - Discovery Labware
Biology Products: